Maxwell Daniel W, Hart Alexandra M, Keifer Orion P, Halani Sameer H, Losken Albert
From the Department of Plastic and Reconstructive Surgery, Emory University Hospital, Atlanta, GA.
Ann Plast Surg. 2019 Apr;82(4):435-440. doi: 10.1097/SAP.0000000000001692.
There is a growing literature of evidence that the use of acellular dermal matrices (ADMs) in abdominal wall reconstruction (AWR) for high-risk patients provides superior complication profiles when compared with standard synthetic mesh. Here we compare Fortiva, Strattice, and Alloderm ADMs in AWR.
In a prospectively maintained database, all patients undergoing AWR between January 2003 and November 2016 were reviewed. Hernia recurrence and surgical site occurrence (SSO) were our primary and secondary endpoints. Kaplan-Meier survival curves and logistic regression models were used to evaluate risks for hernia recurrence and SSO.
A total of 229 patients underwent AWR with 1 of 3 ADMs. Median follow-up time was 20.9 months (1-60 months). Cumulative recurrence rates for each mesh were 6.9%, 11.2%, and 22.0% (P = 0.04), for Fortiva, Strattice, and Alloderm groups. Surgical site occurrence for each mesh was 56.9%, 49.0%, and 49.2%, respectively. Seroma was significantly lower in the Fortiva group (1.4%; P = 0.02). Independent risk factors hernia recurrence included body mass index of 30 kg/m(2) or higher and hypertension. Adjusted risk factors included oncologic resection for hernia recurrence (odds ratio, 5.3; confidence interval, 1.1-97.7; P = 0.11) and a wound class of contaminated or dirty/infected for SSO (odds ratio, 3.6; confidence interval, 1.0-16.6; P = 0.07).
Acellular dermal matrices provide a durable repair with low overall rate of recurrence and complications in AWR. The recurrence and complication profiles differ between brands. With proper patient selection and consideration, ADMs can be used confidently for a variety of indications and wound classifications.
越来越多的证据表明,与标准合成网片相比,高危患者在腹壁重建(AWR)中使用脱细胞真皮基质(ADM)可提供更好的并发症情况。在此,我们比较了Fortiva、Strattice和Alloderm这三种ADM在腹壁重建中的效果。
在一个前瞻性维护的数据库中,对2003年1月至2016年11月期间所有接受腹壁重建的患者进行了回顾。疝复发和手术部位事件(SSO)是我们的主要和次要终点。采用Kaplan-Meier生存曲线和逻辑回归模型来评估疝复发和SSO的风险。
共有229例患者使用三种ADM中的一种进行了腹壁重建。中位随访时间为20.9个月(1 - 60个月)。Fortiva组、Strattice组和Alloderm组每种网片的累积复发率分别为6.9%、11.2%和22.0%(P = 0.04)。每种网片的手术部位事件发生率分别为56.9%、49.0%和49.2%。Fortiva组的血清肿明显更低(1.4%;P = 0.02)。疝复发的独立危险因素包括体重指数为30kg/m²或更高以及高血压。调整后的危险因素包括疝复发的肿瘤切除(比值比,5.3;置信区间,1.1 - 97.7;P = 0.11)和SSO的伤口分类为污染或脏污/感染(比值比,3.6;置信区间,1.0 - 16.6;P = 0.07)。
脱细胞真皮基质在腹壁重建中提供了持久的修复,总体复发率和并发症发生率较低。不同品牌之间的复发和并发症情况有所不同。通过适当的患者选择和考虑,ADM可放心用于各种适应症和伤口分类。